MedTrace Logo

Silymarin in COVID-19 Pneumonia

NCT04394208 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-08-18

No results posted yet for this study

Summary

A randomized placebo controlled trial to assess the clinical outcome in COVID-19 Pneumonia following administration of Silymarin owing to its role as a p38 MAPK pathway inhibitor and its antiviral, anti-inflammatory and anti-oxidant effects

Conditions

  • COVID-19
  • Viral Pneumonia Human Coronavirus

Interventions

DRUG

Silymarin

Silymarin Oral at a dose of 420 mg/day in 3 divided doses.

DRUG

Placebo

Placebo comparator

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-16
Primary Completion
2021-01-30
Completion
2021-02-28

Countries

  • Egypt

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04394208 on ClinicalTrials.gov